Skip to main content

Table 1 Baseline characteristics of 45 patients with locally advanced rectal cancer enrolled in the present study

From: Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study

Characteristic

No. of patients (%)

Age (years)

 ≤ 60

37 (82.2)

 > 60

8 (17.8)

Gender

 Male

25 (55.6)

 Female

20 (44.4)

CEA (mg/mL)

 < 5.00

28 (62.2)

 ≥ 5.00

17 (37.8)

CA19-9 (μg/mL)

 < 27

31 (68.9)

 ≥ 27

14 (31.1)

Clinical T category

 T2

1 (2.2)

 T3

18 (40.0)

 T4a

21 (46.7)

 T4b

5 (11.1)

Clinical N category

 N0

5 (11.1)

 N1

15 (33.3)

 N2

25 (55.6)

Clinical disease category

 Stage II

5 (11.1)

 Stage III

  IIIA

1 (2.2)

  IIIB

12 (26.7)

  IIIC

27 (60)

Location from anal verge (cm)

 0–5

27 (60.0)

 > 5–10

15 (33.3)

 > 10

3 (6.7)

Tumor differentiation

 Well differentiated (G1)

2 (4.4)

 Moderately differentiated (G2)

28 (62.2)

 Poor differentiated (G3)

5 (11.1)

 Other or missing

10 (22.2)